Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection

Bone Marrow Transplantation

Volumn 25, Issue 7, 2000, Pages 757-763

  Einsele, H ^a,c   Hebart, H ^a   Kauffmann Schneider, C ^a   Sinzger, C ^b   Jahn, G ^b   Bader, P ^a   Klingebiel, T ^a   Dietz, K ^b   Loffler J ^a   Bokemeyer, C ^a   Muller C A ^a   Kanz, L ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Medizinische Klinik   (Germany)

Author keywords

BMT; CMV; Late onset disease; PCR; Secondary infections

Indexed keywords

ACICLOVIR; BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; LYMPHOCYTE ANTIBODY; METHOTREXATE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT INFECTION; RISK FACTOR; SIBLING; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 0034037337     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702226     Document Type: Article

References (31)

1. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human bone marrow transplantation. J Infect Dis 1986; 153: 478-488.
2. Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic BMT. Ann Intern Med 1993; 118: 173-178.
3. Winston DJ, Winston GH, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118: 179-184.
4. Schmidt GM, Horac DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. New Engl J Med 1991; 324: 1005-1011.
5. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl J Med 1991; 325: 1601-1607.
6. Van der Bij W, Schirm J, Torensma R et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. J Med Virol 1988; 25: 179.
7. Jiwa JM, Van Gemert GW, Raap AK et al. Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viremic transplant recipients by the polymerase chain reaction. Transplantation 1989; 48: 72-76.
8. Einsele H, Steidle H, Vallbracht A et al. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood 1991; 77: 1104-1110.
9. Einsele H, Ehninger G, Steidle M et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet 1991; 338: 1170-1172.
10. Bacigalupo A, Van Lint MT, Tedone E et al. Early treatment of CMV infection in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marrow Transplant 1994; 13: 753-758.
11. Boeckh M, Bowden RA, Goodrich J et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic bone marrow transplantation. Blood 1992; 80: 1358-1364.
12. Ljungman P, Lore K, Aschan J et al. Use of a semiquantitative PCR assay for cytomegalovirus DNA as a basis for preemptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 583-587.
13. Einsele H, Ehninger G, Hebart H et al. PCR-monitoring after BMT to reduce the incidence of CMV disease and the duration and side effects of antiviral therapy. Blood 1995; 86: 2815-2820.
14. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
15. Lanino E, Anasetti C, Longton G et al. Prevention of cytomegalovirus disease with ganciclovir in recipients of marrow transplants from unrelated donors. Blood 1993; 82 (Suppl. 1) 1359 (Abstr.).
16. Li CR, Greenberg PD, Gilbert MJ et al. HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.
17. Canpolat C, Culbert S, Gardner M et al. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 589-593.
18. Przepiorka D, Ippoliti C, Panina J et al. Ganciclovir three times per week is not adequate to prevent CMV reactivation after T-cell depleted marrow transplantation. Bone Marrow Transplant 1994; 13: 461-464.
19. Atkinson K, Arthur C, Bradstock K et al. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Bone Marrow Transplant 1995; 16: 401-405.
20. Mandanas R, Saez RA, Selby GB, Confer DL. Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy. Am J Hematol 1996; 51: 104-111.
21. Limaye AP, Bowden RA, Myerson D, Boeckh M. Cytomegalovirus disease occurring before engraftment in marrow transplant recipients. Clin Infect Dis 1997; 24: 830-835.
22. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071.
23. Yuen KY, Lo SKF, Chiu EKW et al. Monitoring of leukocyte cytomegalovirus DNA in bone marrow transplant recipients by nested PCR. J Clin Microbiol 1995; 33: 2530-2534.
24. Boeckh M, Bowden RA, Gooley T et al. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 1999; 93: 1781-1782.
25. Boeckh M, Riddell SR, Cunningham T et al. Increased risk of late onset CMV infection and disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T cell responses. Blood 1996; 88 (Suppl. 1): 302a (Abstr. 1195).
26. Zaia JA, Gallez-Hawkins GM, Tegtmeier BR et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997; 176: 782-785.
27. Singhal S, Mehta J, Powles R. Prevention of cytomegalovirus disease by a short course of preemptive ganciclovir or foscarnet. Blood 1994; 84: 2055-2056.
28. Bowden RA, Digel J, Reed EC, Meyers JD. Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses. J Infect Dis 1985; 156: 899-903.
29. Krause H, Hebart H, Jahn G et al. Screening for CMV-specific T-cell proliferation to identify patients at risk to develop late onset CMV disease. Bone Marrow Transplant 1997; 19: 1111-1116.
30. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257: 238-241.
31. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New Engl J Med 1996; 333: 1038-1044.